AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02170259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The articulatory technique
Description: The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
Study NCT04521686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous gemcitabine
Study NCT04521686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous cisplatin
Study NCT04521686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous durvalumab
Study NCT02170259 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined treatment
Description: Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
Study NCT00644566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Care
Description: A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
Study NCT04373694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginoscopy
Description: vaginal distension with hysteroscope for hysteroscopy morcellation (without speculum or tenaculum forceps)
Study NCT04373694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard hysteroscopy
Description: speculum, paracervical block before hysteroscopy morcellation
Study NCT00776009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
Description: 10 mg and/or 20 mg capsules
Study NCT00776009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
Description: 10 mg and/or 20 mg capsules
Study NCT00776009 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study NCT02954237 — intervention group
Intervention type: DEVICE
Intervention: AMPLATZER™ Cardiac Plug
Description: The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
Study NCT02663674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole is a synthetic triazole antifungal agent. It will be supplied as 200 mg over encapsulated tablets. Each gelatin capsule will contain two-100 mg fluconazole tablets and microcrystalline cellulose for overfill.
Study NCT02663674 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as matching gelatin capsules containing microcrystalline cellulose only. Capsules are the same size, weight, and color as capsules containing fluconazole tablets.
Study NCT01823185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
Study NCT01823185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor or prasugrel
Description: ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight \< 60kg) according to local protocol.
Study NCT04676282 — intervention group
Intervention type: OTHER
Intervention: Hypothetical Scenario
Description: Participants will be randomized to one of the arms. Each arm will contain a different hypothetical scenario.
Study NCT01465152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Adminstered orally during the three main meals for 24 weeks
Study NCT01465152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Adminstered orally during the three main meals for 24 weeks
Study NCT01465152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: Administered orally before the three main meals for 24 weeks
Study NCT04303013 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Patients will attend weekly in person guided meditation sessions during the course of their radiation treatment. Patient will complete quality of life surveys before, during and after treatment.
Study NCT04303013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patient not assigned to meditation will undergo radiation with usual care and complete quality of life surveys before, during and after treatment.
Study NCT00542490 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Vaginal Cuff Brachytherapy
Description: Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
Study NCT01262638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 daily for 12 weeks
Study NCT00688753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Study NCT01730391 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: Collection of demographic data and vaccination history
Study NCT01730391 — intervention group
Intervention type: OTHER
Intervention: CSF samples testing
Description: CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
Study NCT01892293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with NY-ESO-1c259-modified T cells
Description: An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to \< 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.~For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given.
Study NCT01713686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin
Study NCT01853761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise after
Description: Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate.
Study NCT01853761 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Exercise after
Description: Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate.
Study NCT01853761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise at same time
Description: Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.~30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate.
Study NCT01853761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneos
Description: Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
Study NCT01853761 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneos
Description: Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
Study NCT01853761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous microcurrent
Description: Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
Study NCT01853761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25-10Hz
Description: microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
Study NCT01853761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 25-50Hz microcurrent
Description: microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
Study NCT03940612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: STP4 (product with probiotics)
Description: STP4 contains Lactobacillus plantarum LP115, Lactobacillus helveticus LA25, Lactobacillus rhamnosus LRH10, Lactobacillus paracasei LPC12, Lactobacillus fermentum LF26, Lactobacillus delbrueckii subsp. lactis, LDL114. Administration at 10 log CFU/day for 8-weeks.
Study NCT03940612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (product without probiotics)
Description: Capsules are similar to STP4 except the presence of probiotics. Administration daily for 8-weeks.
Study NCT02974166 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Group
Description: Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
Study NCT02974166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Group
Description: Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
Study NCT02974166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
Study NCT02974166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
Study NCT02974166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclobenzaprine Hydrochloride
Description: The medication was prescribed by the dentist as muscle relaxer if necessary.
Study NCT02974166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine Hydrochloride
Description: The medication was prescribed by the dentist as muscle relaxer if necessary.
Study NCT02362217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh3NSmut1
Description: Genetic vaccine against Hepatitis C virus infection
Study NCT02362217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-NSmut
Description: Genetic vaccine against Hepatitis C virus infection
Study NCT02362217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdV63.HIVconsv
Description: Genetic vaccine against HIV-1 infection
Study NCT02362217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA.HIVconsv
Description: Genetic vaccine against HIV-1 infection
Study NCT01566890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regadenoson infusion with contrast-enhanced ultrasound
Description: Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
Study NCT01566890 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: contrast-enhanced ultrasound
Description: Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
Study NCT01566890 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: contrast-enhanced ultrasound
Description: Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
Study NCT01566890 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: contrast-enhanced ultrasound
Description: Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
Study NCT01566890 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: contrast-enhanced ultrasound
Description: Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
Study NCT03315065 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Perfluorinated Gas/Oxygen Mixture
Description: 19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, \< 1 hour
Study NCT02376309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inactivity
Description: Inactivity
Study NCT02376309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND
Description: 1 nandrolone decanoate injection
Study NCT02376309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leu
Description: Leucine supplements
Study NCT04176952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX-A
Description: * nab-paclitaxel: 150mg/m2 IV over 30 minutes, day 1 (administered first).~* Oxaliplatin: 85mg/m2, IV over 2 hours, day 1.~* Folinic acid: 350mg flat dose, IV over 2 hours, day 1.~* Fluorouracil infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours or 48 hours as per local practice.)
Study NCT04176952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AG
Description: * nab-paclitaxel: 125mg/m2 IV over 30 minutes on days 1, 8 and 15 (administered first).~* Gemcitabine 1000mg/m2 IV over 30 minutes on days 1, 8 and 15 (immediately following nab-paclitaxel).
Study NCT01933997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metadoxine (MG01CI )
Study NCT02447666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Study NCT04346914 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
Description: ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1\~3，q3w
Study NCT02401711 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education - BIPS course
Description: The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
Study NCT02401711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education - BIPS course
Description: The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
Study NCT02401711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Formal safety curriculum
Description: The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
Study NCT02401711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ongoing evaluation and feedback
Description: The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
Study NCT00967785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mozobil (TM)
Description: twice daily subcutaneous injection or via continuous subcutaneous infusion
Study NCT02529345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RoadSaver stent
Description: lesion treated with RoadSaver stent of Terumo
Study NCT03330730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IsereADOM service package
Description: Objects connected to patients' homes (thermometer, weight scale, tensiometer +/- oximeter, glucose meter or pedometer), Digital liaison booklet, Sentinel referent, Motivational coaching
Study NCT03631472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RheOx
Description: RheOx is a device-based, energy delivery system that delivers energy to ablate soft tissue such as the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope.
Study NCT01354977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 1,000mg twice daily for 28 days
Study NCT03178877 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03527433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New closure technique
Description: In the intervention arm, an average of two sutures will be placed at each cm length of the wound, thus the number of sutures placed should be equal to at least double the length of the wound in cm.The aim is to have a ratio of 4:1 between the overall lengths of the suture to the length of the wound being closed
Study NCT01262638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo daily for 12 weeks
Study NCT03938532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor
Description: Infants in the intervention arm will receive VTV following intubation. Peak inspiratory pressure (PiP) provided via T-piece resuscitator will be visible to the providers, and the provider can regulate the PiP to achieve the desired TV goal (4-6 ml/kg), at a rate of 40-60 breaths/min
Study NCT03938532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tidal Volume Measurement using the Philips Respironics NM3 monitor
Description: Tidal Volume Measurement using the Philips Respironics NM3 monitor
Study NCT04833686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mozart
Description: Music composed by Mozart, a musical piece 24 minutes long.
Study NCT04833686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Instrumental music
Description: Instrumental music , a musical piece 24 minutes long
Study NCT04833686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Silence
Description: Silence, a piece 24 minutes long.
Study NCT01536093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oropharyngeal administration of own mother's colostrum
Description: application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
Study NCT01536093 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oropharyngeal administration of sterile water
Description: application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.